187 related articles for article (PubMed ID: 22941399)
1. Universal immunoassay applied during early development of large molecules to understand impact of immunogenicity on biotherapeutic exposure.
Bautista AC; Salimi-Moosavi H; Jawa V
AAPS J; 2012 Dec; 14(4):843-9. PubMed ID: 22941399
[TBL] [Abstract][Full Text] [Related]
2. Characterization of murine anti-human Fab antibodies for use in an immunoassay for generic quantification of human Fab fragments in non-human serum samples including cynomolgus monkey samples.
Stubenrauch K; Wessels U; Essig U; Kowalewsky F; Vogel R; Heinrich J
J Pharm Biomed Anal; 2013 Jan; 72():208-15. PubMed ID: 23017233
[TBL] [Abstract][Full Text] [Related]
3. Universal immunogenicity validation and assessment during early biotherapeutic development to support a green laboratory.
Bautista AC; Zhou L; Jawa V
Bioanalysis; 2013 Oct; 5(20):2495-507. PubMed ID: 24138623
[TBL] [Abstract][Full Text] [Related]
4. Evaluation of an immunoassay for human-specific quantitation of therapeutic antibodies in serum samples from non-human primates.
Stubenrauch K; Wessels U; Lenz H
J Pharm Biomed Anal; 2009 May; 49(4):1003-8. PubMed ID: 19250787
[TBL] [Abstract][Full Text] [Related]
5. Immunogenicity screening assay development for a novel human-mouse chimeric anti-CD147 monoclonal antibody (Metuzumab).
Mi L; Li W; Li M; Chen T; Wang M; Sun L; Chen Z
J Immunol Methods; 2016 Jun; 433():38-43. PubMed ID: 26944771
[TBL] [Abstract][Full Text] [Related]
6. Quantitative determination of humanized monoclonal antibody rhuMAb2H7 in cynomolgus monkey serum using a Generic Immunoglobulin Pharmacokinetic (GRIP) assay.
Yang J; Ng C; Lowman H; Chestnut R; Schofield C; Sandlund B; Ernst J; Bennett G; Quarmby V
J Immunol Methods; 2008 Jun; 335(1-2):8-20. PubMed ID: 18402977
[TBL] [Abstract][Full Text] [Related]
7. Evaluation of a generic immunoassay with drug tolerance to detect immune complexes in serum samples from cynomolgus monkeys after administration of human antibodies.
Stubenrauch K; Wessels U; Essig U; Vogel R; Schleypen J
J Pharm Biomed Anal; 2010 Jun; 52(2):249-54. PubMed ID: 20083366
[TBL] [Abstract][Full Text] [Related]
8. Strategy and validation of a nonclinical generic plug-and-play antidrug antibody method for human monoclonal antibody biotherapeutics.
Polsky R; Gunn G; Reese KJ; Hottenstein CS; Gehman A; Schwartz A; Root D; Concannon A
Bioanalysis; 2024 Mar; 16(5):277-287. PubMed ID: 38334073
[TBL] [Abstract][Full Text] [Related]
9. Preclinical pharmacokinetics of MFGR1877A, a human monoclonal antibody to FGFR3, and prediction of its efficacious clinical dose for the treatment of t(4;14)-positive multiple myeloma.
Kamath AV; Lu D; Gupta P; Jin D; Xin Y; Brady A; Stephan JP; Li H; Tien J; Qing J; Damico-Beyer LA
Cancer Chemother Pharmacol; 2012 Apr; 69(4):1071-8. PubMed ID: 22203368
[TBL] [Abstract][Full Text] [Related]
10. Development of Rabbit Monoclonal Antibodies for Quantitation of Therapeutic Human Antibodies in Preclinical Non-Human Primate Studies.
Chu R; Gerstein J; Wu H; Huang H; Lou Y; Palmer R
Monoclon Antib Immunodiagn Immunother; 2020 Oct; 39(5):175-183. PubMed ID: 32996830
[TBL] [Abstract][Full Text] [Related]
11. Biomarkers for non-human primate type-I hypersensitivity: antigen-specific immunoglobulin E assays.
Clark D; Shiota F; Forte C; Narayanan P; Mytych DT; Hock MB
J Immunol Methods; 2013 Jun; 392(1-2):29-37. PubMed ID: 23541488
[TBL] [Abstract][Full Text] [Related]
12. An extended range generic immunoassay for total human therapeutic antibodies in preclinical pharmacokinetic studies.
Hall CM; Pearson JT; Patel V; Wienkers LC; Greene RJ
J Immunol Methods; 2013 Jul; 393(1-2):70-3. PubMed ID: 23570944
[TBL] [Abstract][Full Text] [Related]
13. Immune Suppression During Preclinical Drug Development Mitigates Immunogenicity-Mediated Impact on Therapeutic Exposure.
Herskovitz J; Ryman J; Thway T; Lee S; Zhou L; Chirmule N; Meibohm B; Jawa V
AAPS J; 2017 Mar; 19(2):447-455. PubMed ID: 28070711
[TBL] [Abstract][Full Text] [Related]
14. A systematic study of the effect of low pH acid treatment on anti-drug antibodies specific for a domain antibody therapeutic: Impact on drug tolerance, assay sensitivity and post-validation method assessment of ADA in clinical serum samples.
Kavita U; Duo J; Crawford SM; Liu R; Valcin J; Gleason C; Dong H; Gadkari S; Dodge RW; Pillutla RC; DeSilva BS
J Immunol Methods; 2017 Sep; 448():91-104. PubMed ID: 28625864
[TBL] [Abstract][Full Text] [Related]
15. Linear pharmacokinetic parameters for monoclonal antibodies are similar within a species and across different pharmacological targets: A comparison between human, cynomolgus monkey and hFcRn Tg32 transgenic mouse using a population-modeling approach.
Betts A; Keunecke A; van Steeg TJ; van der Graaf PH; Avery LB; Jones H; Berkhout J
MAbs; 2018 Jul; 10(5):751-764. PubMed ID: 29634430
[TBL] [Abstract][Full Text] [Related]
16. Detection of low-affinity anti-drug antibodies and improved drug tolerance in immunogenicity testing by Octet(®) biolayer interferometry.
Li J; Schantz A; Schwegler M; Shankar G
J Pharm Biomed Anal; 2011 Jan; 54(2):286-94. PubMed ID: 20869832
[TBL] [Abstract][Full Text] [Related]
17. Recombinant Anti-idiotypic Antibodies in Ligand Binding Assays for Antibody Drug Development.
Harth S; Frisch C
Methods Mol Biol; 2021; 2261():291-306. PubMed ID: 33420997
[TBL] [Abstract][Full Text] [Related]
18. Preclinical pharmacokinetics of MEHD7945A, a novel EGFR/HER3 dual-action antibody, and prediction of its human pharmacokinetics and efficacious clinical dose.
Kamath AV; Lu D; Gupta P; Jin D; Xiang H; Wong A; Leddy C; Crocker L; Schaefer G; Sliwkowski MX; Damico-Beyer LA
Cancer Chemother Pharmacol; 2012 Apr; 69(4):1063-9. PubMed ID: 22203367
[TBL] [Abstract][Full Text] [Related]
19. Application of blood microsampling in cynomolgus monkey and demonstration of equivalent monoclonal antibody PK parameters compared to conventional sampling.
Wang Y; Crowell SJ; Joyce A; Dyleski L; Messing D; Cargill J; You Z; Murphy S; Gomes M; Gorovits B
Pharm Res; 2021 May; 38(5):819-830. PubMed ID: 33982224
[TBL] [Abstract][Full Text] [Related]
20. Development of a biosensor-based immunogenicity assay capable of blocking soluble drug target interference.
Weeraratne DK; Lofgren J; Dinnogen S; Swanson SJ; Zhong ZD
J Immunol Methods; 2013 Oct; 396(1-2):44-55. PubMed ID: 23933325
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
